Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

MK Brun, GL Goll, KK Jørgensen… - Journal of internal …, 2022 - Wiley Online Library
Abstract Background Anti‐drug antibodies (ADAb) frequently form early in the treatment
course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment …
被引用次数：20 相关文章
[HTML] nih.gov

[HTML][HTML] Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

MK Brun, GL Goll, KK Jørgensen, J Sexton… - Journal of Internal …, 2022 - ncbi.nlm.nih.gov
Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised
controlled trial - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

MK Brun, GL Goll, KK Jørgensen… - Journal of Internal …, 2022 - search.ebscohost.com
Abstract Background: Anti‐drug antibodies (ADAb) frequently form early in the treatment
course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment …

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

MK Brun, GL Goll, KK Jørgensen, J Sexton… - Journal of Internal …, 2022 - duo.uio.no
Background Anti-drug antibodies (ADAb) frequently form early in the treatment course of
infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and …

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

MK Brun, GL Goll, KK Jørgensen, J Sexton, JE Gehin… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Anti-drug antibodies (ADAb) frequently form early in the treatment course of
infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and …

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

MK Brun, GL Goll, KK Jørgensen, J Sexton… - Journal of Internal …, 2022 - europepmc.org
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised
controlled trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …